IPO Boutique

Cara Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Cara Therapeutics, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Cara TherapeuticsCARA -
NASDAQ
$11.00-$13.00 $11.00 $11.625 million1/31/2014
Stifel, Piper Jaffray
Co-Manager(s):
Canaccord Genuity, Needham & Co., Janney Montgomery Scott
Health Care
Filing(s):

Filed 2013-11-08



Cara Therapeutics Quote & Chart - Click for current quote - CARA

About Cara Therapeutics (adapted from Cara Therapeutics prospectus):
They are a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "CARA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved